» Articles » PMID: 38569684

Metabolic Dysfunction-associated Profiles and Subsequent Site-specific Risk of Obesity-related Cancers Among Chinese Patients with Diabetes: a Retrospective Cohort Study

Overview
Journal BMJ Open
Specialty General Medicine
Date 2024 Apr 3
PMID 38569684
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To compare metabolic dysfunction-associated profiles between patients with diabetes who developed different obesity-related site-specific cancers and those who remained free of cancer during follow-up.

Design: Retrospective cohort study.

Setting: Public general outpatient clinics in Hong Kong.

Participants: Patients with diabetes without a history of malignancy (n=391 921).

Primary Outcome Measures: The outcomes of interest were diagnosis of site-specific cancers (colon and rectum, liver, pancreas, bladder, kidney and stomach) during follow-up. Cox proportional hazards regression was applied to assess the associations between metabolic dysfunction and other clinical factors with each site-specific cancer.

Results: Each 0.1 increase in waist-to-hip ratio was associated with an 11%-35% elevated risk of colorectal, bladder and liver cancers. Each 1% increase in glycated haemoglobin was linked to a 4%-9% higher risk of liver and pancreatic cancers. While low-density lipoprotein cholesterol and triglycerides were inversely associated with the risk of liver and pancreatic cancers, high-density lipoprotein cholesterol was negatively associated with pancreatic, gastric and kidney cancers, but positively associated with liver cancer. Furthermore, liver cirrhosis was linked to a 56% increased risk of pancreatic cancer. No significant association between hypertension and cancer risk was found.

Conclusions: Metabolic dysfunction-associated profiles contribute to different obesity-related cancer outcomes differentially among patients with diabetes. This study may provide evidence to help identify cancer prevention targets during routine diabetes care.

References
1.
Hecht S . Cigarette smoking: cancer risks, carcinogens, and mechanisms. Langenbecks Arch Surg. 2006; 391(6):603-13. DOI: 10.1007/s00423-006-0111-z. View

2.
Kim G, Kang E . Prevention of Hepatocellular Carcinoma by Statins: Clinical Evidence and Plausible Mechanisms. Semin Liver Dis. 2019; 39(2):141-152. DOI: 10.1055/s-0039-1679956. View

3.
Abdalla M, El-Arabey A, Gai Z . PDL-1 and insulin resistance in obesity: a possible pathway for macrovascular disease. Hum Cell. 2024; 37(2):568-570. DOI: 10.1007/s13577-024-01029-2. View

4.
Morin E, Li X, Schwendeman A . HDL in Endocrine Carcinomas: Biomarker, Drug Carrier, and Potential Therapeutic. Front Endocrinol (Lausanne). 2018; 9:715. PMC: 6283888. DOI: 10.3389/fendo.2018.00715. View

5.
Kalaitzakis E, Gunnarsdottir S, Josefsson A, Bjornsson E . Increased risk for malignant neoplasms among patients with cirrhosis. Clin Gastroenterol Hepatol. 2010; 9(2):168-74. DOI: 10.1016/j.cgh.2010.10.014. View